Clarus Therapeutics Holdings Inc (CE) (CRXTQ) Quote

CRXTQ: Bankruptcy PLAN effective. All shares and warrants cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

One year ago this was $5.00. They prevailed over LPCN in a lawsuit. What went so terribly wrong to cause such a downfall?

Effective Sept. 7,2022 CRXT will change to CRXTQ, bankruptcy.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

CRXT delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

Only enough $$ thru September. Bankrupt very possible.

CRXT

Out @.162..

Took a trade position @.115 for a quickie..

Down another 25%. Watch but ..."If the Company is not able to restructure its indebtedness and obtain necessary capital, it may be required to discontinue its commercialization efforts for JATENZO, liquidate all or a portion of its assets and/or seek protection under the provisions of the U.S. Bankruptcy Code.”

No bottom?

CRXT

#CRXT ! Loading cheapies here, waiting for 1.00 dollar break then 1 year target

of $9.00 bucks $$$$$$$$$$$$$ #oversold #buythefear #reapbankslater

#CRXT @0.53 Up 23% ! Squeeeezing the shorts !! $1.00 dollar break near folks

$9.00 Target

SHORT SQUEEZE $$$ #CRXT $1.00 plus next week $$$

Long term target $9.00

OVERSOLD !! Watch for a run back to $1.00 plus soon imo.

#CRXT

Biotechs are toxic in this crappy market

#CRXT @0.46 Rated a buy with $9.00 price target $$$$

Needham Thinks Clarus Therapeutics Holdings’ Stock is Going to Recover
May 17 2022 - 06:16AM
TipRanks
Alert


Needham analyst Serge Belanger maintained a Buy rating on Clarus Therapeutics Holdings (CRXT – Research Report) today and set a price target of $3.00. The company's shares closed last Monday at $0.54, close to its 52-week low of $0.42. According to TipRanks.com, Belanger is a 2-star analyst with an average return of -0.3% and a 40.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals. Clarus Therapeutics Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.00. See the top stocks recommended by analysts >> The company has a one-year high of $9.
https://www.tipranks.com/news/blurbs/needham-thinks-clarus-therapeutics-holdings-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral

Looking for $1.00 plus after quarter reports today

#CRXT

If it goes below 7 Il get more

Taking a starter

$crxt

Boooooming indeed !!!

#CRXT $$$$$$$$$$$$$$$$$$$$

I see nice

BOOM

Looks like they are stepping out again

Everyone stopped out and now the rip market is brutal

Off to the races we go !!!

#CRXT

Break 0.70 & we got a massive gainer

#CRXT

.68

$1.00 plus this week imo.

$10.00 plus by summer time $$$

#CRXT $$$$$

whoa

Till it goes to .01

How long can this stay under 1.00 without being delisted?

Take a look at Duo

$1,00 plus this week imo. #OVERSOLD

#TargetPPS$10.00 Bucks $$$

#CRXT

Don’t see it yet

Big bounce next week imo.

problably $1.00 plus

#CRXT

Looks like it’s headed to 52wk low then it’s showtime

They’re not regretting anything. We’re getting porked again today.

those selling will regret MARK IT $$$$

They now have $50 million in cash.

Strong balance sheet.

Nearly 80 percent institutional ownership.


This stock is fixing to skyrocket.


This price is a damn steal.

Agree let’s gooo$$$

A notice of allowance is issued by the United States Patent & Trademark Office to indicate that it believes an invention qualifies for a patent. However, the person originally filing for the patent is not fully protected until he completes the rest of the patent process and pays the appropriate fees.

This is good news this morning if they can follow through. Stock is up and going in the right direction - time to accumulate!

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

Source: GlobeNewswire Inc.

Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the closing of its previously announced underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock (or pre-funded warrant) was sold together with one Class A warrant at a combined purchase price of $1.10 per unit (or $1.10 (less) $0.001 (the exercise price of the pre-funded warrants) for units comprising pre-funded warrants and accompanying Class A warrants). The Class A warrants are immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Class A warrants could only be purchased together in the offering, but were issued separately and were immediately separable upon issuance. The pre-funded warrants and the Class A warrants are not listed on any exchange. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding the proceeds from the exercise of any Class A warrants, were approximately $30.0 million. In addition, Clarus has granted the underwriters a 45-day option to purchase up to an additional 4,090,608 shares of common stock and/or Class A warrants to purchase up to 4,090,608 shares of common stock to cover over-allotments at the offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 4,090,608 Class A warrants.
Clarus expects to use the net proceeds from the offering, together with its existing cash, for working capital and other general corporate purposes.

Maxim Group LLC acted as sole book-running manager for the offering.

Registration statements on Form S-1 relating to the securities have been filed with the U.S. Securities and Exchange Commission (SEC) and become effective. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Contact:
Kara Stancell
Vice President, Investor Relations & Corporate Communications
kstancell@clarustherapeutics.com
(847) 562-4300 x 206

It’s going to run hard

Some idiots selling/buying back and forth! FFS let it run! I need my $2.50+ back!

How is this not flying lol

Closing News! - https://flashalert.me/?symbol=CRXT&source=PR&referer=https://stocktwits.com/&url=https://www.globenewswire.com/news-release/2022/04/27/2430605/19989/en/Clarus-Therapeutics-Announces-Closing-of-Upsized-30-0-Million-Underwritten-Public-Offering.html&s3=CRXT/2022-04-27/13-45-46_000000/glob/1e7c7066761d4c31b8bb2da3ed8cc177/Clarus-Therapeutics-Announces-Closing-of-Upsized-30-0-Million-Underwritten-Public-Offering.html

Good ? Don’t know

What happens if the share price does not go to $1.10+ at closing? Does the company take back the proposal? Or Has someone already purchased those millions of shares and now there at a substantial loss?

Something is brewing here

Break that $1